Discovery of benzamide analogs as negative allosteric modulators of human neuronal nicotinic receptors: Pharmacophore modeling and structure-activity relationship studies

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 15, 2013, Pages 4730-4743

  Yi, Bitna ^a   Long, Sihui ^a   González Cestari, Tatiana F ^a   Henderson, Brandon J ^a,b   Pavlovicz, Ryan E ^a   Werbovetz, Karl ^a   Li, Chenglong ^a   McKay, Dennis B ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Negative allosteric modulators; Neuronal nicotinic receptors; Pharmacophore modeling; Structure activity relationship studies

Indexed keywords

4 (ALLYLOXY) N (6 BROMOPYRIDIN 2 YL)BENZAMIDE; 4 (ALLYLOXY) N (6 CHLOROPYRIDIN 2 YL)BENZAMIDE; 4 (ALLYLOXY) N (6 ETHYLPYRIDIN 2 YL)BENZAMIDE; 4 (ALLYLOXY) N (6 METHYLPYRIDIN 2 YL)BENZAMIDE; 4 (ALLYLOXY) N [6 (PROPYLAMINO)PYRIDIN 2 YL]BENZAMIDE; 4 (ALLYLOXY)BENZOIC ACID; 4 PROPOXY N (PYRAZIN 2 YL)BENZAMIDE; 4 PROPOXY N [6 (BUTYLAMINO)PYRIDIN 2 YL]BENZAMIDE; 4 PROPOXY N [6 (PROPYLAMINO)PYRIDIN 2 YL]BENZAMIDE; ALLY 4 (ALLYLOXY)BENZOATE; BENZAMIDE DERIVATIVE; N (6 BROMOPYRIDIN 2 YL) 4 PROPOXYBENZAMIDE; N (6 BROMOPYRIDIN 2 YL)ACETAMIDE; N (6 CHLOROPYRIDIN 2 YL) 4 PROPOXYBENZAMIDE; N (6 ETHYLPYRIDIN 2 YL) 4 PROPOXYBENZAMIDE; N (6 METHYLPYRIDIN 2 YL) 4 PROPOXYBENZAMIDE; N [6 (BENZYLAMINO)PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 (BUTYLAMINO)PYRIDIN 2 YL]ACETAMIDE; N [6 (HEXYLAMINO)PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 (PENTYLAMINO)PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 (PHENYLAMINO)PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 (PIPERIDIN 1 YL)PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 (PROPYLAMINO)PYRIDIN 2 YL]ACETAMIDE; N [6 [(2 FLUOROPHENYL)AMINO]PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 [(3 FLUOROPHENYL)AMINO]PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 [(4 CHLOROPHENYL)AMINO]PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 [(4 FLUOROPHENYL)AMINO]PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; N [6 [(4 METHOXYPHENYL)AMINO]PYRIDIN 2 YL] 4 PROPOXYBENZAMIDE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHEMICAL MODEL; DRUG ACTIVITY; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 84879686742     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.03.082     Document Type: Article

References (30)

1. J.A. Dani, and D. Bertrand Annu. Rev. Pharmacol. Toxicol. 47 2007 699
2. G.K. Lloyd, F. Menzaghi, B. Bontempi, C. Suto, R. Siegel, M. Akong, K. Stauderman, G. Velicelebi, E. Johnson, M.M. Harpold, T.S. Rao, A.I. Sacaan, L.E. Chavez-Noriega, M.S. Washburn, J.M. Vernier, N.D.P. Cosford, and L.A. McDonald Life Sci. 62 1998 1601
3. A. Taly, P.-J. Corringer, D. Guedin, P. Lestage, and J.-P. Changeux Nat. Rev. Drug Disc. 8 2009 733
4. R.J. Lukas, J.-P. Changeux, N. le Novère, E.X. Albuquerque, J.K. Balfour, D.K. Berg, D. Bertrand, V.A. Chiappinelli, P.B.S. Clarke, A.C. Collins, J.A. Dani, S.R. Grady, K.J. Kellar, J.M. Lindstrom, M.J. Marks, M. Quik, P.W. Taylor, and S. Wonnacott Pharmacol. Rev. 51 1999 397
5. R.L. Papke Prog. Neurobiol. 41 1993 509
6. C. Gotti, M. Zoli, and F. Clementi Trends Pharmacol. Sci. 27 2006 482
7. D. Goldman, E. Deneris, W. Luyten, A. Kochhar, J. Patrick, and S. Heinemann Cell 48 1987 965
8. B.K. Cassels, I. Bermudez, F. Dajas, A. Abin-Carriquiry, and S. Wonnacott Drug Discovery Today 10 2007 1657
9. A.R. Tapper, S.L. McKinney, R. Nashmi, J. Schwarz, P. Deshpande, C. Labarca, P. Whiteaker, M.J. Marks, A.C. Collins, and H.A. Lester Science 306 2004 1029
10. A.R. Tapper, S.L. McKinney, M.J. Marks, and H.A. Lester Physiol. Genomics 31 2007 422
11. M.R. Picciotto, M. Zoli, R. Rimondini, C. Léna, L.M. Marubio, E.M. Pich, K. Fuxe, and J.-P. Changeux Nature 391 1998 173
12. M.R. Picciotto, M. Zoli, V. Zachariou, and J.-P. Changeux Biochem. Soc. Trans. 25 1997 824
13. B.J. Henderson, D.J. Carper, T.F. González-Cestari, B. Yi, K.V. Mahasenan, R.E. Pavlovicz, M.L. Dalefield, R.S. Coleman, C. Li, and D.B. McKay J. Med. Chem. 54 2011 8681
14. K.V. Mahasenan, R.E. Pavlovicz, B.J. Henderson, T.F. González- Cestari, B. Yi, D.B. McKay, and C. Li ACS. Med. Chem. Lett. 2011 http://dx.doi.org/10.1021/ml2001714
15. T.F. González-Cestari, B.J. Henderson, R.E. Pavlovicz, S.B. McKay, R.A. El Hajj, A.B. Pulipaka, C.M. Orac, D.D. Reed, R.T. Boyd, M.X. Zhu, C. Li, S.C. Bergmeier, and D.B. McKay J. Pharmacol. Exp. Ther. 328 2009 504
16. B.J. Henderson, R.E. Pavlovicz, J.D. Allen, T.F. Gonzalez-Cestari, C.M. Orac, A.B. Bonnel, M.X. Zhu, R.T. Boyd, C. Li, S.C. Bergmeier, and D.B. McKay J. Pharmacol. Exp. Ther. 334 2010 761
17. B.J. Henderson, T.F. González-Cestari, B. Yi, R.E. Pavlovicz, R.T. Boyd, C. Li, S.C. Bergmeier, and D.B. McKay ACS Chem. Neurosci. 2012 10.1021/cn300035f
18. R.E. Pavlovicz, B.J. Henderson, A.B. Bonnel, R.T. Boyd, D.B.McKay, and C. Li, Identification of a negative allosteric site on human a4�2 and a3�4 neuronal nicotinic acetylcholine receptors, PLoS ONE(2011), pp:e24949, doi:10.1371/journal.pone.0024949
19. G. Pickaert, M. Cesario, and R. Ziessel J. Org. Chem. 69 2004 5335
20. S. Wagaw, and S.L. Buchwald J. Org. Chem. 61 1996 7240
21. W.L. Jorgensen Science 303 2004 1813
22. G.F. Yang, and X. Huang Curr. Pharm. Des. 12 2006 4601
23. B.K. Shoichet, S.L. McGovern, B. Wei, and J.J. Irwin Curr. Opin. Chem. Biol. 6 2002 439 446
24. W.P. Walters, M. Stahl, and M.A. Murcko Drug Discovery Today 3 1998 160
25. A.N. Jain Curr. Opin. Drug Disc. Dev. 7 2004 396 403
26. W.B. Floriano, N. Vaidehi, G. Zamanakos, and W.A. Goddard III J. Med. Chem. 47 2004 56
27. D.B. McKay, and A.M. Burkman Proc. Soc. Exp. Biol. Med. 203 1993 372
28. D.B. McKay, and A.P. Sanchez Pharmacology 40 1990 224
29. B.J. Henderson, C.M. Orac, I. Maciagiewicz, S.C. Bergmeier, and D.B. McKay Bioorg. Med. Chem. Lett. 22 2012 1797
30. D.B. McKay, C. Cheng, T.F. González-Cestari, S.B. McKay, R. El-Hajj, D.L. Bryant, P.W. Swaan, K.M. Arason, A.B. Pulipaka, C.M. Orac, and S.C. Bergmeier Mol. Pharmacol. 71 2007 1288